Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Lantern Pharma Inc. (LTRN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 8-K Investor presentation, Quarterly results
Docs: "Lantern Pharma Reports Second Quarter 2023 Financial Results and Operational Highlights"
05/09/2023 8-K Investor presentation, Quarterly results
Docs: "Lantern Pharma Reports First Quarter 2023 Financial Results and Operational Highlights"
03/20/2023 8-K Quarterly results
01/18/2023 8-K Quarterly results
11/07/2022 8-K Investor presentation, Quarterly results
Docs: "Lantern Pharma Reports Third Quarter 2022 Financial Results and Operational Highlights &#9679"
08/08/2022 8-K Quarterly results
06/14/2022 8-K Quarterly results
05/03/2022 8-K Quarterly results
04/26/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Important Additional Information and Where to Find It"
04/25/2022 8-K Other Events  Interactive Data
03/22/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Lantern Pharma Announces Extension of Existing Share Repurchase Program DALLAS, March 22, 2022 /PRNewswire/ -- Lantern Pharma Inc. , a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence and machine learning platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that its Board of Directors has authorized an extension through July 31, 2022 of Lantern’ s existing share repurchase program to acquire up to $7 million of the Company’ s common stock. Since the initiation of the share repurchase program in November 2021, a total of 475,157 shares of common stock have been repurchased pursuant to Lantern’ s share repurchase program. Total expenditures for share repurchases from the time of initiation of..."
03/10/2022 8-K Investor presentation
Docs: "Lantern Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Operational Highlights",
"NASDAQ:LTRN NEW CANCER CATEGORIES RADR"
01/24/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "INVESTOR CONTACT:"
11/22/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "www.lanternpharma.com"
11/01/2021 8-K Investor presentation, Quarterly results
Docs: "November 1st , 2021 4:30 PM Eastern Third quarter 2021 Operating & Financial Results Conference Call / Webinar TODAY’ S SPEAKERS Panna Sharma Chief Financial Officer and Secretary Chief Scientific Officer Finance and A d m inis t r a t i o n Chief Executive Officer, President and Director David Margrave Dr. Kishor Bhatia Nicole Leber NASDAQ:LTRN 1",
"Lantern Pharma Reports Third Quarter 2021 Financial Results and Operating Highlights"
07/29/2021 8-K Investor presentation, Quarterly results
Docs: "Lantern Pharma Reports Second Quarter 2021 Financial Results and Operational Highlights",
"Presentation relating to July 29, 2021 conference call and live webcast to discuss financial and operating results for quarter ended June 30, 2021"
05/25/2021 8-K Quarterly results
05/03/2021 8-K Quarterly results
03/10/2021 8-K Quarterly results
10/29/2020 8-K Investor presentation, Quarterly results
Docs: "Condensed Consolidated Balance Sheets September 30, December 31, 2020 2019 CURRENT ASSETS Cash $ 20,802,542 $ 1,232,030 Prepaid expenses and other current assets 1,672,802 788 Total current assets 22,475,344 1,232,818 Property and equipment, net 17,608 8,758 Deferred offering costs - 191,000 TOTAL ASSETS $ 22,492,952 $ 1,432,576 CURRENT LIABILITIES Accounts payable and accrued expenses $ 814,557 $ 489,292 Total current liabilities 814,557 489,292 Loan payable 108,500 - TOTAL LIABILITIES 923,057 489,292 STOCKHOLDERS’ EQUITY Preferred Stock - Par Value - 244 Common Stock – Par Value 622 198 Additional paid-in capital 31,333,164 7,694,547 Accumulated deficit Total stockholders’ equity 21,569,895 943,284 TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 22,492,952 $ 1,432,576 5 Condensed Consoli...",
"Presentation relating to October 29, 2020 conference call and live webcast to discuss financial and operating results for quarter ended September 30, 2020"
08/21/2020 8-K Quarterly results
07/30/2020 8-K Quarterly results
07/16/2020 8-K Quarterly results
06/16/2020 8-K Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Even...
Docs: "AMENDMENT TO CERTIFICATE OF INCORPORATION",
"AMENDED AND RESTATED CERTIFICATE OF INCORPORATION",
"PRESS RELEASE ANNOUNCING THE CLOSING OF THE INITIAL PUBLIC OFFERING"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy